Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta ® (pertuzumab) to Herceptin ® (trastuzumab) and chemotherapy 21% reduction in the risk of death was seen in the pre-specified subgroup of people with lymph node-positive disease Data to be presented as a late-breaking abstract at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer... Read More